Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)
Brief Summary: The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): 3
B: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C
D: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only

Answer: D